Cue Biopharma logo

Cue Biopharma Share Price Today

(NASDAQ: CUE)

Cue Biopharma share price is $0.76 & ₹64.95 as on 18 Apr 2025, 2.30 'hrs' IST

$0.76

-0.02

(-2.18%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Cue Biopharma share price in Dollar and Rupees. Guide to invest in Cue Biopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cue Biopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Cue Biopharma share price movements

  • Today's Low: $0.75
    Today's High: $0.80

    Day's Volatility :6.24%

  • 52 Weeks Low: $0.45
    52 Weeks High: $2.26

    52 Weeks Volatility :80.09%

Cue Biopharma (CUE) Returns

PeriodCue Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
-37.02%
-2.8%
0.0%
6 Months
-54.64%
-11.0%
0.0%
1 Year
-51.15%
-1.9%
0.0%
3 Years
-82.36%
-1.5%
-12.9%

Cue Biopharma (CUE) Key Statistics

in dollars & INR

Previous Close
$0.779
Open
$0.7665
Today's High
$0.8
Today's Low
$0.7501
Market Capitalization
$57.4M
Today's Volume
$111.5K
52 Week High
$2.26
52 Week Low
$0.45
Revenue TTM
$9.3M
EBITDA
$-41.2M
Earnings Per Share (EPS)
$-0.72
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-149.03%

How to invest in Cue Biopharma Stock (CUE) from India?

It is very easy for Indian residents to invest directly in Cue Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cue Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cue Biopharma or CUE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cue Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cue Biopharma shares which would translate to 1.125 fractional shares of Cue Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cue Biopharma, in just a few clicks!

Returns in Cue Biopharma (CUE) for Indian investors in Rupees

The Cue Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cue Biopharma investment value today

Current value as on today

₹51,059

Returns

₹48,941

(-48.94%)

Returns from Cue Biopharma Stock

₹51,282 (-51.28%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Cue Biopharma (CUE)

150%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Cue Biopharma Stock from India on INDmoney has increased by 150% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Cue Biopharma

  • Bleichroeder LP

    8.08%

  • Vanguard Group Inc

    3.33%

  • BlackRock Inc

    1.03%

  • Geode Capital Management, LLC

    1.02%

  • Robertson Stephens Wealth Management, LLC

    0.77%

  • Sigma Planning Corp

    0.72%

Analyst Recommendation on Cue Biopharma

Rating
Trend

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Cue Biopharma(by analysts ranked 0 to 5 stars)

Analyst Forecast on Cue Biopharma Stock (CUE)

What analysts predicted

Upside of 360.53%

Target:

$3.50

Current:

$0.76

Insights on Cue Biopharma Stock (Ticker Symbol: CUE)

  • Price Movement

    In the last 3 months, CUE stock has moved down by -40.5%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.33M → 1.57M (in $), with an average decrease of 52.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.66M → -9.49M (in $), with an average decrease of 9.7% per quarter
  • CUE vs ONC (1 yr)

    In the last 1 year, Beone Medicines Ltd has given 76.1% return, outperforming this stock by 126.2%
  • CUE vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 28.9% return, outperforming this stock by 111.7%
  • Price to Sales

    ForCUE every $1 of sales, investors are willing to pay $4.6, whereas for Beone Medicines Ltd, the investors are paying $6.4 for every $1 of sales.

Cue Biopharma Technicals Summary

Sell

Neutral

Buy

Cue Biopharma is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cue Biopharma (CUE) Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Cue Biopharma Inc logo
-18.85%
-54.64%
-51.15%
-82.36%
-96.46%
Regeneron Pharmaceuticals, Inc. logo
-17.1%
-41.85%
-37.2%
-21.74%
-0.85%
Beone Medicines Ltd logo
-13.12%
5.03%
78.34%
40.23%
43.44%
Vertex Pharmaceuticals Incorporated logo
-4.76%
2.3%
24.05%
71.43%
78.99%
Alnylam Pharmaceuticals, Inc. logo
-9.09%
-19.67%
62.43%
39.66%
61.91%

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Organization
Cue Biopharma
Employees
41
CEO
Mr. Daniel R. Passeri J.D., M.Sc.
Industry
Health Technology

Management People of Cue Biopharma

NameTitle
Mr. Daniel R. Passeri J.D., M.Sc.
CEO & Director
Ms. Kerri-Ann Millar CPA
Chief Financial Officer
Dr. Ronald D. Seidel III, Ph.D.
Co-Founder
Dr. Rodolfo J. Chaparro Ph.D.
Co-Founder & Senior Advisor
Dr. Steven C. Almo Ph.D.
Co-Founder and Chairman of Scientific & Clinical Advisory Board
Mr. Colin G. Sandercock J.D., MSE
Senior VP, General Counsel & Secretary
Dr. Matteo Levisetti M.D.
Chief Medical Officer
Ms. Lucinda Warren
Chief Business Officer
Dr. Daniel G. Baker M.D., Ph.D.
Interim Chief Development Officer

Important FAQs about investing in CUE Stock from India :

What is Cue Biopharma share price today?

Cue Biopharma share price today stands at $0.76, Open: $0.77 ; Previous Close: $0.78 ; High: $0.80 ; Low: $0.75 ; 52 Week High: $2.26 ; 52 Week Low: $0.45.

The stock opens at $0.77, after a previous close of $0.78. The stock reached a daily high of $0.80 and a low of $0.75, with a 52-week high of $2.26 and a 52-week low of $0.45.

Can Indians buy Cue Biopharma shares?

Yes, Indians can invest in the Cue Biopharma (CUE) from India.

With INDmoney, you can buy Cue Biopharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cue Biopharma at zero transaction cost.

How can I buy Cue Biopharma shares from India?

It is very easy to buy Cue Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cue Biopharma (CUE) be purchased?

Yes, you can buy fractional shares of Cue Biopharma with INDmoney app.

What are the documents required to start investing in Cue Biopharma stocks?

To start investing in Cue Biopharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Cue Biopharma Stock (CUE)?

Today’s highest price of Cue Biopharma (CUE) is $0.80.

Today’s lowest price of Cue Biopharma (CUE) is $0.75.

What is today's market capitalisation of Cue Biopharma?

Today's market capitalisation of Cue Biopharma CUE is 57.4M

What is the 52 Week High and Low Range of Cue Biopharma Stock (CUE)?

  • 52 Week High

    $2.26

  • 52 Week Low

    $0.45

What are the historical returns of Cue Biopharma (CUE)?

  • 1 Month Returns

    -18.85%

  • 3 Months Returns

    -54.64%

  • 1 Year Returns

    -51.15%

  • 5 Years Returns

    -96.46%

Who is the Chief Executive Officer (CEO) of Cue Biopharma ?

Mr. Daniel R. Passeri J.D., M.Sc. is the current Chief Executive Officer (CEO) of Cue Biopharma.